<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Dopamine-receptor agonists: Parkinson's disease; Pramipexole; Ropinirole; Rotigotine; Bromocriptine: Parkinson's disease; Cabergoline: Parkinson's disease; Pergolide; Apomorphine" /><meta name="IX" content="Dopamine-receptor agonists: Parkinson's disease; Pramipexole; Ropinirole; Rotigotine; Bromocriptine: Parkinson's disease; Cabergoline: Parkinson's disease; Pergolide; Apomorphine" /><title>Dopamine-receptor agonists: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP3057-dopamine-receptor-agonists.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP3057-dopamine-receptor-agonists.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP3057-dopamine-receptor-agonists.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP2092-central-nervous-system.htm">4 Central nervous system</a> &gt; <a href="PHP3054-drugs-used-in-parkinsonism-and-related-disorders.htm">4.9 Drugs used in parkinsonism and related disorders</a> &gt; <a href="PHP3056-dopaminergic-drugs-used-in-parkinsons-disease.htm">4.9.1 Dopaminergic drugs used in Parkinson's disease</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP3056-dopaminergic-drugs-used-in-parkinsons-disease.htm" title="Previous: 4.9.1 Dopaminergic drugs used in Parkinson's disease">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP3063-apomorphine-hydrochloride.htm" title="Next: APOMORPHINE HYDROCHLORIDE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Dopamine-receptor agonists</h1><?highlighter on?><div id="pC" class="jN"><p>The dopamine-receptor agonists have a direct action on dopamine receptors. Initial treatment of Parkinson's disease is often with the dopamine-receptor agonists <strong>pramipexole</strong>, <strong>ropinirole</strong>, and <strong>rotigotine</strong>. The ergot-derived dopamine-receptor agonists <strong>bromocriptine</strong>, <strong>cabergoline</strong>,  and <strong>pergolide</strong> are rarely used because the risk of fibrotic reactions (see <a title="BNF:target-block: Fibrotic reactions" href="PHP3057-dopamine-receptor-agonists.htm#PHP3060">notes below</a>).</p> <p>When used alone, dopamine-receptor agonists cause fewer motor complications in long-term treatment compared with levodopa treatment but the overall motor performance improves slightly less. The dopamine-receptor agonists are associated with more psychiatric side-effects than levodopa.</p> <p>Dopamine-receptor agonists are also used with levodopa in more advanced disease. If a dopamine-receptor agonist is added to levodopa therapy, the dose of levodopa needs to be reduced (see individual monographs).</p> <div class="cI"><h3 class="cT">Impulse control disorders</h3><p id="PHP3058">Treatment with dopamine-receptor agonists and levodopa is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist or levodopa should be withdrawn or the dose reduced until the symptoms resolve.</p></div> <p id="PHP3059">Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.</p> <div class="cI" id="PHP3060"><h3 class="cT">Fibrotic reactions</h3><p>Ergot-derived dopamine-receptor agonists, bromocriptine, cabergoline, and pergolide, have been associated with pulmonary, retroperitoneal, and pericardial fibrotic reactions. </p><p>Exclude cardiac valvulopathy with echocardiography before starting treatment with these ergot derivatives for Parkinson's disease or chronic endocrine disorders (excludes suppression of lactation); it may also be appropriate to measure the erythrocyte sedimentation rate and serum creatinine and to obtain a chest X-ray. Patients should be monitored for dyspnoea, persistent cough, chest pain, cardiac failure, and abdominal pain or tenderness. If long-term treatment is expected, then lung-function tests may also be helpful. Patients taking cabergoline or pergolide should be regularly monitored for cardiac fibrosis by echocardiography (within 3–6 months of initiating treatment and subsequently at 6–12 month intervals).</p></div> <div class="cI" id="PHP3061"> <h3>Driving</h3><div><div class="cE"><h3 class="cT">Sudden onset of sleep</h3> <p class="cT">Excessive daytime sleepiness and sudden onset of sleep can occur with co-careldopa, co-beneldopa, and dopamine-receptor agonists.</p></div><p>Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.</p><p>Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.</p></div><div><div class="cE"><h3 class="cT">Hypotensive reactions</h3> <p class="cT">Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.</p></div></div></div> <p id="PHP3062"><strong>Apomorphine</strong> is a potent dopamine-receptor agonist that is sometimes helpful in advanced disease for patients experiencing unpredictable ‘off’ periods with levodopa treatment. Apomorphine should be initiated in a specialist clinic with at least two days pretreatment with <a title="BNF:monograph: DOMPERIDONE" href="PHP2544-domperidone.htm">domperidone</a> for nausea and vomiting. After an overnight withdrawal of oral antiparkinsonian medication to induce an ‘off’ episode, the threshold dose of apomorphine is determined. Oral antiparkinsonian medication is then restarted. The patient must be taught to self-administer apomorphine by subcutaneous injection into the lower abdomen or outer thigh at the first sign of an ‘off' episode. Once treatment has been established it may be possible to gradually reduce other antiparkinsonian medications and reduce or withdraw domperidone therapy. Treatment with apomorphine should remain under specialist supervision.</p> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP3063-apomorphine-hydrochloride"><a href="PHP3063-apomorphine-hydrochloride.htm" title="APOMORPHINE HYDROCHLORIDE">APOMORPHINE HYDROCHLORIDE</a></li><li id="_PHP3066-bromocriptine"><a href="PHP3066-bromocriptine.htm" title="BROMOCRIPTINE">BROMOCRIPTINE</a></li><li id="_PHP3068-cabergoline"><a href="PHP3068-cabergoline.htm" title="CABERGOLINE">CABERGOLINE</a></li><li id="_PHP3072-pergolide"><a href="PHP3072-pergolide.htm" title="PERGOLIDE">PERGOLIDE</a></li><li id="_PHP3075-pramipexole"><a href="PHP3075-pramipexole.htm" title="PRAMIPEXOLE">PRAMIPEXOLE</a></li><li id="_PHP3080-ropinirole"><a href="PHP3080-ropinirole.htm" title="ROPINIROLE">ROPINIROLE</a></li><li id="_PHP3087-rotigotine"><a href="PHP3087-rotigotine.htm" title="ROTIGOTINE">ROTIGOTINE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP3056-dopaminergic-drugs-used-in-parkinsons-disease.htm">Previous: 4.9.1 Dopaminergic drugs used in Parkinson's disease</a> | <a class="top" href="PHP3057-dopamine-receptor-agonists.htm#">Top</a> | <a accesskey="]" href="PHP3063-apomorphine-hydrochloride.htm">Next: APOMORPHINE HYDROCHLORIDE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>